SCHEMBL2380917

SCHEMBL2380917

O=C(Cl)c1cccc2cc(-c3cccc4cnccc34)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.47
DGAT2 Q96PD7 3/20 0.44
NTSR1 P30989 1/20 0.43
KDR P35968 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
CHEK1 O14757 1/20 0.41
ERN1 O75460 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
EPHX2 P34913 1/20 0.41
MCL1 Q07820 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TNF P01375 1/20 0.38
BRAF P15056 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
CYP11B1 P15538 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2380673 0.88 MCL1 (0.49) SERPINE1DGAT2NTSR1KDRPIK3CD
SCHEMBL2381295 0.87 KDM4E (0.46) SERPINE1DGAT2NTSR1KDRPIK3CD
SCHEMBL14571338 0.87 DGAT2 (0.46) SERPINE1DGAT2NTSR1KDRPIK3CD
SCHEMBL17040876 0.85 KDM4E (0.55) SLC22A12KDM4EMAPKAPK2TRPV1
SCHEMBL2379174 0.84 DGAT2 (0.55) SERPINE1DGAT2NTSR1KDRCHEK1
SCHEMBL2380276 0.81 KDR (0.58) SERPINE1DGAT2KDR
SCHEMBL2380392 0.81 KDR (0.60) SERPINE1KDRKDM4EBRAF
SCHEMBL12245746 0.80 KDR (0.61) SERPINE1KDR
SCHEMBL2380952 0.79 DGAT2 (0.58) SERPINE1DGAT2NTSR1KDRCHEK1
SCHEMBL12245751 0.78 DGAT2 (0.57) DGAT2KDRCHEK1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017601-B2 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2011-09-13 US disclosed
EP-1896461-A2 BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER Amgen Inc. (US) 2008-03-12 EP disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 US disclosed
WO-2007005668-A2 BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054903-A1 Bis-aryl kinase inhibitors and method HGF, MET, BLK SERPINE1 1913/4885DGAT2 3636/4885NTSR1 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.